Reply
Hui Ma, Bing Xia – 27 July 2022
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
- Read more about AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro – 26 July 2022
Inhibition of lysyl oxidase‐like 2 overcomes adhesion‐dependent drug resistance in the collagen‐enriched liver cancer microenvironment
Lanqi Gong, Yu Zhang, Yuma Yang, Qian Yan, Jifeng Ren, Jie Luo, Yuen Chak Tiu, Xiaona Fang, Beilei Liu, Raymond Hiu Wai Lam, Ka‐On Lam, Anne Wing‐Mui Lee, Xin‐Yuan Guan – 26 July 2022 – The tumor microenvironment (TME) is considered to be one of the vital mediators of tumor progression. Extracellular matrix (ECM), infiltrating immune cells, and stromal cells collectively constitute the complex ecosystem with varied biochemical and biophysical properties.
Up‐regulated LRRN2 expression as a marker for graft quality in living donor liver transplantation
Takahiro Tomiyama, Takuya Yamamoto, Shokichi Takahama, Takeo Toshima, Shinji Itoh, Noboru Harada, Mototsugu Shimokawa, Daisuke Okuzaki, Masaki Mori, Tomoharu Yoshizumi – 26 July 2022 – The quality and size of liver grafts are critical factors that influence living‐donor liver transplantation (LDLT) function and safety. However, the biomarkers used for predicting graft quality are lacking. In this study, we sought to identify unique graft quality markers, aside from donor age, by using the livers of non‐human primates.
Clinical phenotype of adult‐onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1
Jeremy S. Nayagam, Pierre Foskett, Sandra Strautnieks, Kosh Agarwal, Rosa Miquel, Deepak Joshi, Richard J. Thompson – 26 July 2022 – Variants in ATP8B1, ABCB11, and ABCB4 underlie the most prevalent forms of progressive familial intrahepatic cholestasis. We aim to describe variants in these genes in a cohort of patients with adult‐onset liver disease, and explore a genotype–phenotype correlation. Patients with onset of liver disease aged above 18 who underwent sequencing of cholestasis genes for clinical purposes over a 5‐year period were identified.
Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct‐acting antivirals
Sheri Trudeau, Vivek Mendiratta, Yara Dababneh, Jennifer Hollingsworth, Stuart C. Gordon – 26 July 2022
Direct chemical induction of hepatocyte‐like cells with capacity for liver repopulation
Yunfei Bai, Zhenghao Yang, Xiaochan Xu, Wanqiu Ding, Juntian Qi, Feng Liu, Xiaoxiao Wang, Bin Zhou, Wenpeng Zhang, Xiaomei Zhuang, Guanglu Li, Yang Zhao – 25 July 2022
Letter to the editor: County‐level variation in hepatitis C virus mortality and trends in the United States, 2005–2017
Muhammad Shehryar, Muhammad Zawar Asif, Muhammad Umair – 25 July 2022
The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
Zobair M. Younossi, Yusuf Yilmaz, Mohamed El‐Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahum Méndez‐Sánchez, Wah Kheong Chan, Ashwani K. Singal, Brian Lam, Sean Felix, Elena Younossi, Manisha Verma, Jillian K. Price, Fatema Nader, Issah Younossi, Andrei Racila, Maria Stepanova – 25 July 2022 – Patients with preexisting chronic liver disease (CLD) may experience a substantial burden from both coronavirus 2019 (COVID‐19) infection and pandemic‐related life disruption. We assessed the impact of the COVID‐19 pandemic on patients with CLD.
Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation
Muhammad H. Raza, Yong Kwon, Pierre Kobierski, Asish C. Misra, Angelina Lim, Cameron Goldbeck, Kambiz Etesami, Rohit Kohli, Juliet Emamaullee – 24 July 2022 – Hepatopulmonary syndrome (HPS) is associated with increased waitlist mortality in liver transplantation (LT) candidates. Children with HPS are granted Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) exception points for waitlist prioritization in the United States based on criterion developed for adults.